Connect with us

Featured

Google Fined $1.7 Billion By European Commision​

Daniel Chase

Published

on

stock_price_google

You know that shady character that lives down the street from your apartment, and every time you see him, you give him the change in your pocket, but you always question what he’s really up to? Well, that may be due to a number of reasons, namely that something may have occurred in your childhood which has subsequently caused you to either fear the homeless or have trust issues. In some scenarios, an individual could have both fear and mistrust in their hearts.

As time has progressed and technological advancements have followed suit, societal trust in tech companies has dwindled. Though we expect the brilliant minds of this generation and the next to pioneer technologies to improve our lives for the better, secretly, like the man down the street, we question what they’re really up to. 

Back in December, just before the strike of the new year, Google (GOOGL), the Company heralded for providing the world with access to information in less time than it takes America to forget about a natural disaster, shared with the world that the personal data of 52.5 million Google + users  was comprised due  to a bug discovered in connection with a Google + API. Suffice to say, the search engine-backed tech behemoth quickly addressed the issue, especially given the rising fears of consumers in regards to what websites do with their personal data. 

It seemed, at least for the last few months, that Google (GOOGL) was in the clear. The Company yesterday made headlines with its announcement of of a video game streaming service called Stadia which will allow users to play the game that they love without the need for purchasing wallet-emptying consoles or computers. 

Per the details of the official announcement, with Stadia, YouTube watchers will be able to click “Play now” at the end of a video and their game will start within five seconds. Perhaps the craziest part about Stadia is that the “data center is the platform,” meaning that players can start at one platform and continue where they left off on any advice capable of connecting to Google. 

However, we’ve come to learn that behind all the glitz and glamor, some tech companies are always up to no good. On Wednesday, the European Commission slapped Google (GOOGL) with a fine for breaching EU antitrust rules. According to the official press release regarding the matter, Google has abused its market dominance by imposing a number of restrictive clauses in contracts with third-party websites which hinders any rival of the Company from placing their own ads on these sites. 

In other words, Google (GOOGL) has structured the online advertising playing field in their favor. 

“Today the commission has fined Google €1.49 billion for illegal misuse of its dominant position in the market for the brokering of online search adverts. Google has cemented its dominance in online search adverts and shielded itself from competitive pressure by imposing anti-competitive contractual restrictions on third-party websites. This is illegal under EU antitrust rules. The misconduct lasted over 10 years and denied other companies the possibility to compete on the merits and to innovate – and consumers the benefits of competition…”

Margrethe Vestager, Commissioner, European Commission 

The European Commission shared that over the course of the last few years, through AdSense for Search, Google (GOOGL) has held market shared above 90% in the national markets for general search, making it near impossible for competitors in online search advertising to sell ad space within Google’s search engine results pages. 

Continue Reading
Click to comment

Featured

Stock Price Wednesday Morning Update – November 13, 2019

Joe Samuel

Published

on

stock market news

3 Biotech Stocks to Watch After Key, 4th Quarter Developments

Biotech stocks have been one of the best performing sectors for a few weeks now. It’s hardly surprising that many analysts believe that investors should have one or more of those stocks on their watch lists. However, when it comes to choosing a stock, an investor needs to be very diligent with research. What are some companies to watch?

See For Yourself


3 Defense Stocks to Watch in November

The current unstable geopolitical situation in different corners of the world could lead to even more defense spending if a Bank of America analyst is to be believed. Hence, it is worthwhile to have a look at a few stocks that could prove to benefit from this latest trend.

Click Here For More


The $40 Billion Dollar Content Gold Rush

Some reports such as one from Grand View Research have stated “The global video streaming market size is anticipated to reach USD $124.57 Billion by 2025. It is anticipated to expand at a CAGR of 19.6% during the forecast period.” What companies stand to prosper?

Read More

Continue Reading

Biotechnology

3 Biotech Stocks to Watch After Key, 4th Quarter Developments

Joe Samuel

Published

on

top biotech stocks to buy

Biotech stocks have been one of the best performing sectors for a few weeks now. It’s hardly surprising that many analysts believe that investors should have one or more of those stocks on their watch lists. However, when it comes to choosing a stock, an investor needs to be very diligent with research.

They also need to watch the market very closely for the latest movements. Making a list of the stocks to watch is the best way to go about it. On that note, here is a look at three biotech stocks solidifying big developments this quarter.

PharmaCyte Biotech (PMCB)

top biotech stocks to buy now

PharmaCyte Biotech (PMCB) is in the prep phase of clinical trials and readying to complete its Investigational New Drug Application for the FDA.  Whether you’re new to biotech stocks or a seasoned vet, you should understand how important milestones like this are for a company.

David A. Judd, a cellular biologist and a member of PharmaCyte’s Medical and Scientific Advisory Board, was recently interviewed. Right now, PharmaCyte Biotech (PMCB) is putting together the necessary material for its planned clinical trial for inoperable pancreatic cancer, one of the most deadly forms of cancer today.

“We are in the late stages of preparing an Investigational New Drug application (IND) to conduct a clinical trial involving patients with LAPC whose tumors no longer respond to either of these two first-line therapies,” stated Pharmacyte in a recent article*.  “We hope to be in a position to file our IND in 2019.  [Pharmacyte is] in the process of developing the final data we need to finish preparation of the IND by completing the second of two staggered and back-to-back manufacturing runs of our clinical trial product.”

As one report puts it, “Clinical trials are essential for the development of new treatments, and PharmaCyte will enter this upcoming trial with two essential goals in mind—the future of its pancreatic cancer treatment and the future of its technology.”

Dare Bioscience (DARE)

best penny stocks Clovis Oncology (CLVS)

The first biotech stock that should be put on the watch list is that of Dare Bioscience Inc (NASDAQ:DARE). The Dare stock has soared in yesterday’s session the back of a significant announcement from the company. Dare is involved in the development of innovative health solutions for women and today entered into an agreement to acquire the pioneering drug delivery technology developed by Microchips Biotech Inc.

The technology in question can help in storing and delivering hundreds of doses over a period of as much as a year. It is a significant development for Dare and the stock has jumped by as much as 8% after the news. This is definitely a stock that should be tracked closely.

Agenus (AGEN)

The other biotech stock that has made a strong start this week is that of Agenus Inc (NASDAQ:AGEN), an immuno-oncology company. on Monday, the company announced that it has reached a licensing agreement with UroGen Pharma Ltd for its product zalifrelimab. More importantly, Agenus has received $10 million upfront from UroGen and that sent the stock price higher by 9.24% on Monday.

November has been a good month for the stock and so far it has gained as much as 45%. It released its quarterly results on November 4 and it proved a pleasant surprise for investors. The loss per share came in at $0.33, which beat analysts’ estimates of $0.38. On the other hand, the revenues of $19.94 also managed to surpass analysts’ estimates by 27.82%.

best biotech stocks to trade now

Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer.

Continue Reading

Featured

Stock Price Newsletter – November 12, 2019

Jon Phillip

Published

on

list of healthcare stocks to watch

Biotech Stocks To Watch This Week

Biotech penny stocks have proven to be one of the best sectors for investments. That’s as far as the stock market is concerned. If experts are to be believed then it may continue to be among the best options in the years to come…

Continue Reading


Streaming Stocks Take Aim At Winning The Content War

It has been projected that the industry is going to be worth $124.57 billion by 2025. That being said, there may be ample opportunity for investors. Here is a look at a few tech stocks to watch that could be set to prove themselves on this new battlefield.

See For Yourself


What Does The Disney (DIS) Plus, Amazon Deal Mean For Investors?

There is no doubt that 2019 and the years beyond are going to be definite by the ‘streaming wars’ between some of the biggest companies in the world. The imminent entry of a behemoth like Disney (DIS) has raised the stakes even higher and on Thursday the entertainment company made another significant announcement.

Click To Read More

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com